EA202092154A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA202092154A1
EA202092154A1 EA202092154A EA202092154A EA202092154A1 EA 202092154 A1 EA202092154 A1 EA 202092154A1 EA 202092154 A EA202092154 A EA 202092154A EA 202092154 A EA202092154 A EA 202092154A EA 202092154 A1 EA202092154 A1 EA 202092154A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapy
inhibitor
effective amount
methods
kinase
Prior art date
Application number
EA202092154A
Other languages
English (en)
Inventor
Дэниел П. Голд
Original Assignee
Мей Фарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк. filed Critical Мей Фарма, Инк.
Publication of EA202092154A1 publication Critical patent/EA202092154A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способам лечения заболеваний, таких как рак, с применением комбинированной терапии. В конкретных вариантах выполнения изобретения способы включают введение пациенту эффективного количества ингибитора фосфоинозитид-3-киназы (PI3K) и эффективного количества ингибитора тирозинкиназы Брутона (БТК).
EA202092154A 2018-03-21 2019-03-20 Комбинированная терапия EA202092154A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862646314P 2018-03-21 2018-03-21
PCT/US2019/023172 WO2019183226A1 (en) 2018-03-21 2019-03-20 Combination therapy

Publications (1)

Publication Number Publication Date
EA202092154A1 true EA202092154A1 (ru) 2021-03-22

Family

ID=67988025

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092154A EA202092154A1 (ru) 2018-03-21 2019-03-20 Комбинированная терапия

Country Status (16)

Country Link
US (1) US20210000838A1 (ru)
EP (1) EP3768258A4 (ru)
JP (1) JP2021517116A (ru)
KR (1) KR20200135439A (ru)
CN (1) CN112165939A (ru)
AU (1) AU2019238207A1 (ru)
BR (1) BR112020019082A2 (ru)
CA (1) CA3093847A1 (ru)
EA (1) EA202092154A1 (ru)
IL (1) IL277336A (ru)
MA (1) MA52090A (ru)
MX (1) MX2020009773A (ru)
SG (1) SG11202009137PA (ru)
TW (1) TW202002983A (ru)
WO (1) WO2019183226A1 (ru)
ZA (1) ZA202005661B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
SG11201601844TA (en) 2013-09-13 2016-04-28 Beigene Ltd Anti-pd1 antibodies and their use as therapeutics and diagnostics
JP6526189B2 (ja) 2014-07-03 2019-06-05 ベイジーン リミテッド 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
EP4353747A3 (en) 2016-08-19 2024-06-26 BeiGene Switzerland GmbH Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
KR20200009088A (ko) 2017-05-23 2020-01-29 메이 파마, 아이엔씨. 병용 요법
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
CN111212643A (zh) 2017-08-14 2020-05-29 梅制药公司 联合疗法
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
JP2022538215A (ja) * 2019-06-10 2022-09-01 ベイジーン スウィッツァーランド ゲーエムベーハー 経口カプセルおよびその調製方法
CN113939289A (zh) * 2019-06-10 2022-01-14 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691384B1 (en) * 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
KR20150141971A (ko) * 2013-04-08 2015-12-21 파마싸이클릭스 엘엘씨 이브루티닙 병용 요법
JP2016540053A (ja) * 2013-12-05 2016-12-22 アセルタ ファーマ ビー．ブイ． Ｐｉ３ｋ阻害剤とｂｔｋ阻害剤の治療的組み合わせ
US9949971B2 (en) * 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
TW201618774A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法

Also Published As

Publication number Publication date
JP2021517116A (ja) 2021-07-15
CA3093847A1 (en) 2019-09-26
SG11202009137PA (en) 2020-10-29
AU2019238207A1 (en) 2020-10-01
US20210000838A1 (en) 2021-01-07
WO2019183226A1 (en) 2019-09-26
MX2020009773A (es) 2020-10-08
KR20200135439A (ko) 2020-12-02
IL277336A (en) 2020-10-29
BR112020019082A2 (pt) 2020-12-29
EP3768258A1 (en) 2021-01-27
MA52090A (fr) 2021-04-21
CN112165939A (zh) 2021-01-01
EP3768258A4 (en) 2022-01-12
TW202002983A (zh) 2020-01-16
ZA202005661B (en) 2023-05-31

Similar Documents

Publication Publication Date Title
EA202092154A1 (ru) Комбинированная терапия
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
MX2019003134A (es) Terapia de combinacion.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA201792304A1 (ru) Комбинированная терапия для лечения рака
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201791535A1 (ru) Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201790870A1 (ru) Трициклические атропоизомерные соединения
PH12021550443A1 (en) Pyridazinones and methods of use thereof
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2021007554A (es) Terapia de combinacion para el tratamiento de cancer.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA202190360A1 (ru) Комбинированная терапия